Cargando…

L’utilisation de l’approche CTC: quel impact sur la couverture vaccinale lors de la campagne préventive de vaccination contre la méningite A avec le MenAfriVac au Togo en 2014?

METHOD: We conducted a survey from 9 to 14 March 2015 (for approximately 3 months) after the end of the vaccination campaign in these four regions. Interviewees were selected using two stages cluster sampling stratified according to the regions. MenAfriVac vaccine in Controlled Temperature Chain (CT...

Descripción completa

Detalles Bibliográficos
Autores principales: Landoh, Dadja Essoya, Kahn, Anna-Léa, Lacle, Anani, Adjeoda, Kodjovi, Saka, Bayaki, Yaya, Issifou, Nassoury, Danladi Ibrahim, Kalao, Assima, Makawa, Makawa-Sy, Biey, Nsiari-Mueyi Joseph, Bita, Andre, Toke, Yaovi Temfa, Dörte, Petit, Imboua, Lucile, Ronveaux, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The African Field Epidemiology Network 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5516651/
https://www.ncbi.nlm.nih.gov/pubmed/28761614
http://dx.doi.org/10.11604/pamj.2017.27.38.11873
_version_ 1783251196403777536
author Landoh, Dadja Essoya
Kahn, Anna-Léa
Lacle, Anani
Adjeoda, Kodjovi
Saka, Bayaki
Yaya, Issifou
Nassoury, Danladi Ibrahim
Kalao, Assima
Makawa, Makawa-Sy
Biey, Nsiari-Mueyi Joseph
Bita, Andre
Toke, Yaovi Temfa
Dörte, Petit
Imboua, Lucile
Ronveaux, Olivier
author_facet Landoh, Dadja Essoya
Kahn, Anna-Léa
Lacle, Anani
Adjeoda, Kodjovi
Saka, Bayaki
Yaya, Issifou
Nassoury, Danladi Ibrahim
Kalao, Assima
Makawa, Makawa-Sy
Biey, Nsiari-Mueyi Joseph
Bita, Andre
Toke, Yaovi Temfa
Dörte, Petit
Imboua, Lucile
Ronveaux, Olivier
author_sort Landoh, Dadja Essoya
collection PubMed
description METHOD: We conducted a survey from 9 to 14 March 2015 (for approximately 3 months) after the end of the vaccination campaign in these four regions. Interviewees were selected using two stages cluster sampling stratified according to the regions. MenAfriVac vaccine in Controlled Temperature Chain (CTC) was used in 10 districts, in Togo. RESULTS: A total of 2707 households were surveyed and 9082 people aged 1-29 years were interviewed. The average age of the individuals surveyed was 11.8±7.7 years and sex-ratio (H/F) was 1.01. The average number of individuals per household was 5.7 and that of persons aged 1-29 years targeted in the campaign was 3.4. Out of 9082 people surveyed 8889 (98%) were vaccinated. Multivariate analysis showed that the factors associated with immunization coverage using MenAfrivac vaccine were: habitual residence in the area at the time of the campaign (AOR = 4.52; 95%CI = [4.07 - 4.97]) and level of information about the campaign before it starts (AOR=2.42; 95%CI = [2.05 - 2.80]). By contrast, there were no differences in vaccination coverage between the areas based on whether the CTC approach was used or not (AOR=0.09; 95%CI = [-0.27 - 0.45]). Two hundred and seven respondents (2.3%) reported that they had Adverse Event Following Immunisation (AEFI) after the administration of the vaccine. These were usually minor AEFI involving fever, abscesses and swelling at the injection site. CONCLUSION: Survey results show that the use of CTC in a country with limited resources such as Togo doesn't have a negative impact on immunization coverage. Indeed, there was no difference between immunization coverage in CTC and non-CTC areas. It is important to capitalize on the experience gained in order to use vaccines by Expanded Program of Immunization in CTC approach especially in countries with limited resources in terms of cold chain availability.
format Online
Article
Text
id pubmed-5516651
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher The African Field Epidemiology Network
record_format MEDLINE/PubMed
spelling pubmed-55166512017-07-31 L’utilisation de l’approche CTC: quel impact sur la couverture vaccinale lors de la campagne préventive de vaccination contre la méningite A avec le MenAfriVac au Togo en 2014? Landoh, Dadja Essoya Kahn, Anna-Léa Lacle, Anani Adjeoda, Kodjovi Saka, Bayaki Yaya, Issifou Nassoury, Danladi Ibrahim Kalao, Assima Makawa, Makawa-Sy Biey, Nsiari-Mueyi Joseph Bita, Andre Toke, Yaovi Temfa Dörte, Petit Imboua, Lucile Ronveaux, Olivier Pan Afr Med J Research METHOD: We conducted a survey from 9 to 14 March 2015 (for approximately 3 months) after the end of the vaccination campaign in these four regions. Interviewees were selected using two stages cluster sampling stratified according to the regions. MenAfriVac vaccine in Controlled Temperature Chain (CTC) was used in 10 districts, in Togo. RESULTS: A total of 2707 households were surveyed and 9082 people aged 1-29 years were interviewed. The average age of the individuals surveyed was 11.8±7.7 years and sex-ratio (H/F) was 1.01. The average number of individuals per household was 5.7 and that of persons aged 1-29 years targeted in the campaign was 3.4. Out of 9082 people surveyed 8889 (98%) were vaccinated. Multivariate analysis showed that the factors associated with immunization coverage using MenAfrivac vaccine were: habitual residence in the area at the time of the campaign (AOR = 4.52; 95%CI = [4.07 - 4.97]) and level of information about the campaign before it starts (AOR=2.42; 95%CI = [2.05 - 2.80]). By contrast, there were no differences in vaccination coverage between the areas based on whether the CTC approach was used or not (AOR=0.09; 95%CI = [-0.27 - 0.45]). Two hundred and seven respondents (2.3%) reported that they had Adverse Event Following Immunisation (AEFI) after the administration of the vaccine. These were usually minor AEFI involving fever, abscesses and swelling at the injection site. CONCLUSION: Survey results show that the use of CTC in a country with limited resources such as Togo doesn't have a negative impact on immunization coverage. Indeed, there was no difference between immunization coverage in CTC and non-CTC areas. It is important to capitalize on the experience gained in order to use vaccines by Expanded Program of Immunization in CTC approach especially in countries with limited resources in terms of cold chain availability. The African Field Epidemiology Network 2017-05-12 /pmc/articles/PMC5516651/ /pubmed/28761614 http://dx.doi.org/10.11604/pamj.2017.27.38.11873 Text en © Dadja Essoya Landoh et al. http://creativecommons.org/licenses/by/2.0/ The Pan African Medical Journal - ISSN 1937-8688. This is an Open Access article distributed under the terms of the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Landoh, Dadja Essoya
Kahn, Anna-Léa
Lacle, Anani
Adjeoda, Kodjovi
Saka, Bayaki
Yaya, Issifou
Nassoury, Danladi Ibrahim
Kalao, Assima
Makawa, Makawa-Sy
Biey, Nsiari-Mueyi Joseph
Bita, Andre
Toke, Yaovi Temfa
Dörte, Petit
Imboua, Lucile
Ronveaux, Olivier
L’utilisation de l’approche CTC: quel impact sur la couverture vaccinale lors de la campagne préventive de vaccination contre la méningite A avec le MenAfriVac au Togo en 2014?
title L’utilisation de l’approche CTC: quel impact sur la couverture vaccinale lors de la campagne préventive de vaccination contre la méningite A avec le MenAfriVac au Togo en 2014?
title_full L’utilisation de l’approche CTC: quel impact sur la couverture vaccinale lors de la campagne préventive de vaccination contre la méningite A avec le MenAfriVac au Togo en 2014?
title_fullStr L’utilisation de l’approche CTC: quel impact sur la couverture vaccinale lors de la campagne préventive de vaccination contre la méningite A avec le MenAfriVac au Togo en 2014?
title_full_unstemmed L’utilisation de l’approche CTC: quel impact sur la couverture vaccinale lors de la campagne préventive de vaccination contre la méningite A avec le MenAfriVac au Togo en 2014?
title_short L’utilisation de l’approche CTC: quel impact sur la couverture vaccinale lors de la campagne préventive de vaccination contre la méningite A avec le MenAfriVac au Togo en 2014?
title_sort l’utilisation de l’approche ctc: quel impact sur la couverture vaccinale lors de la campagne préventive de vaccination contre la méningite a avec le menafrivac au togo en 2014?
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5516651/
https://www.ncbi.nlm.nih.gov/pubmed/28761614
http://dx.doi.org/10.11604/pamj.2017.27.38.11873
work_keys_str_mv AT landohdadjaessoya lutilisationdelapprochectcquelimpactsurlacouverturevaccinalelorsdelacampagnepreventivedevaccinationcontrelameningiteaaveclemenafrivacautogoen2014
AT kahnannalea lutilisationdelapprochectcquelimpactsurlacouverturevaccinalelorsdelacampagnepreventivedevaccinationcontrelameningiteaaveclemenafrivacautogoen2014
AT lacleanani lutilisationdelapprochectcquelimpactsurlacouverturevaccinalelorsdelacampagnepreventivedevaccinationcontrelameningiteaaveclemenafrivacautogoen2014
AT adjeodakodjovi lutilisationdelapprochectcquelimpactsurlacouverturevaccinalelorsdelacampagnepreventivedevaccinationcontrelameningiteaaveclemenafrivacautogoen2014
AT sakabayaki lutilisationdelapprochectcquelimpactsurlacouverturevaccinalelorsdelacampagnepreventivedevaccinationcontrelameningiteaaveclemenafrivacautogoen2014
AT yayaissifou lutilisationdelapprochectcquelimpactsurlacouverturevaccinalelorsdelacampagnepreventivedevaccinationcontrelameningiteaaveclemenafrivacautogoen2014
AT nassourydanladiibrahim lutilisationdelapprochectcquelimpactsurlacouverturevaccinalelorsdelacampagnepreventivedevaccinationcontrelameningiteaaveclemenafrivacautogoen2014
AT kalaoassima lutilisationdelapprochectcquelimpactsurlacouverturevaccinalelorsdelacampagnepreventivedevaccinationcontrelameningiteaaveclemenafrivacautogoen2014
AT makawamakawasy lutilisationdelapprochectcquelimpactsurlacouverturevaccinalelorsdelacampagnepreventivedevaccinationcontrelameningiteaaveclemenafrivacautogoen2014
AT bieynsiarimueyijoseph lutilisationdelapprochectcquelimpactsurlacouverturevaccinalelorsdelacampagnepreventivedevaccinationcontrelameningiteaaveclemenafrivacautogoen2014
AT bitaandre lutilisationdelapprochectcquelimpactsurlacouverturevaccinalelorsdelacampagnepreventivedevaccinationcontrelameningiteaaveclemenafrivacautogoen2014
AT tokeyaovitemfa lutilisationdelapprochectcquelimpactsurlacouverturevaccinalelorsdelacampagnepreventivedevaccinationcontrelameningiteaaveclemenafrivacautogoen2014
AT dortepetit lutilisationdelapprochectcquelimpactsurlacouverturevaccinalelorsdelacampagnepreventivedevaccinationcontrelameningiteaaveclemenafrivacautogoen2014
AT imboualucile lutilisationdelapprochectcquelimpactsurlacouverturevaccinalelorsdelacampagnepreventivedevaccinationcontrelameningiteaaveclemenafrivacautogoen2014
AT ronveauxolivier lutilisationdelapprochectcquelimpactsurlacouverturevaccinalelorsdelacampagnepreventivedevaccinationcontrelameningiteaaveclemenafrivacautogoen2014